Ernexa Therapeutics (ERNAW) EPS (Basic) (2010 - 2026)
Ernexa Therapeutics' (ERNAW) quarterly EPS (Basic) came in at -$6.95 in Q1 2026, up 87.94% YoY from -$3.7 in Q1 2025, and down 16.15% on a QoQ basis from -$5.99 in Q4 2025.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) EPS (Basic) (2010 - 2026) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 17 years of EPS (Basic) data on file, last reported at -$6.95 in Q1 2026.
- Quarterly EPS (Basic) rose 87.94% year-over-year to -$6.95 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.4 (up 95.56% YoY) and the FY2025 annual result came in at -$55.89, up 95.43% from the prior year.
- EPS (Basic) declined to -$6.95 in Q1 2026, from -$5.99 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$3.77 in Q3 2025 to a low of -$1.3 million in Q1 2022.
- A 5-year average of -$79157.6 and a median of -$387.54 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) sank 26704.51% — and 2023, when it jumped 99.97%.
- Tracing ERNAW's EPS (Basic) over 5 years: stood at -$552.73 in 2022, then grew by 21.34% to -$434.76 in 2023, then soared by 63.55% to -$158.46 in 2024, then jumped by 96.22% to -$5.99 in 2025, then declined by 16.15% to -$6.95 in 2026.
- The last three EPS (Basic) figures came in at -$6.95 (Q1 2026), -$5.99 (Q4 2025), and -$3.77 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - | -3.40 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.40 |
| Mar 31, 2026 | -6.95 |
| Dec 31, 2025 | -0.24 |
| Sep 30, 2025 | -0.15 |
| Jun 30, 2025 | -0.61 |
| Mar 31, 2025 | -2.31 |
| Dec 31, 2024 | -6.34 |
| Sep 30, 2024 | -73.76 |
| Jun 30, 2024 | -15.35 |
| Mar 31, 2024 | -18.43 |
| Dec 31, 2023 | -17.39 |
| Sep 30, 2023 | -15.50 |
| Jun 30, 2023 | -12.77 |
| Mar 31, 2023 | -15.84 |
| Dec 31, 2022 | -22.11 |
| Sep 30, 2022 | -37.31 |
| Jun 30, 2022 | -17.38 |
| Mar 31, 2022 | -52.45 |
| Dec 31, 2021 | -55.15 |
| Sep 30, 2021 | -510.38 |